Genetic Technologies Limited (NASDAQ: GENE) is 24.17% higher on its value in year-to-date trading and has touched a low of $1.41 and a high of $10.30 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The GENE stock was last observed hovering at around $5.01 in the last trading session, with the day’s loss setting it -0.54% off its average median price target of $25.65 for the next 12 months. It is also 82.57% off the consensus price target high of $25.65 offered by 1 analysts, but current levels are 82.57% higher than the price target low of $25.65 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $4.47, the stock is -10.24% and 2.32% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.39 million and changing -10.78% at the moment leaves the stock 29.33% off its SMA200. GENE registered 20.49% gain for a year compared to 6-month gain of 9.02%. The firm has a 50-day simple moving average (SMA 50) of $4.7506 and a 200-day simple moving average (SMA200) of $3.8101.
The stock witnessed a -19.46% loss in the last 1 month and extending the period to 3 months gives it a 49.50%, and is -18.73% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 14.72% over the week and 9.40% over the month.
Distance from 52-week low is 217.40% and -56.60% from its 52-week high.
Genetic Technologies Limited (GENE) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Genetic Technologies Limited (GENE) is a “Buy”. 1 analysts offering their recommendations for the stock, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Genetic Technologies Limited quarterly earnings per share for the current quarter are estimated at $0.The EPS is expected to shrink by -157.90% this year.
Genetic Technologies Limited (GENE) Top Institutional Holders
14 institutions hold shares in Genetic Technologies Limited (GENE), with 175.84k shares held by insiders accounting for 1.28% while institutional investors hold 1.42% of the company’s shares. The shares outstanding are 15.02M, and float is at 11.79M with Short Float at 11.67%. Institutions hold 1.41% of the Float.
The top institutional shareholder in the company is Susquehanna International Group, LLP with over 75512.0 shares valued at $0.27 million. The investor’s holdings represent 0.50% of the GENE Shares outstanding. As of Dec 30, 2020, the second largest holder is Susquehanna Fundamental Investments, LLC with 64600.0 shares valued at $0.23 million to account for 0.43% of the shares outstanding. The other top investors are Citadel Advisors LLC which holds 24073.0 shares representing 0.16% and valued at over $86662.0, while Virtu Financial LLC holds 0.16% of the shares totaling 23954.0 with a market value of $82880.0.